This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n6	http://linked.opendata.cz/resource/mesh/concept/
rdfs	http://www.w3.org/2000/01/rdf-schema#
n7	http://linked.opendata.cz/resource/fda-spl/ingredient/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n5	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
nci	http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n8	http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item

nci:C224

rdf:type

owl:Class

rdfs:label

Allopurinol

rdfs:subClassOf

nci:C1637 nci:C921

nci:A5

nci:C2564

nci:A8

nci:C63923

nci:P106

Pharmacologic Substance Organic Chemical

nci:P108

Allopurinol

nci:P175

1390 101655

nci:P207

C0002144

nci:P210

315-30-0

nci:P319

63CZ7GJN5I

nci:P322

FDA

nci:P325

<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A drug that lowers high levels of uric acid (a byproduct of metabolism) in the blood caused by some cancer treatments.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>

nci:P329

38452

nci:P330

38452

nci:P350

C5H4N4O

nci:P366

Allopurinol

nci:P368

CHEBI:40279

nci:P90

<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Sigapurol</n0:term-name><n0:term-group>FB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>4&#39;-HPP</n0:term-name><n0:term-group>AB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>1H-Pyrazolo[3,4-d]pyrimidin-4-ol</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>1,5-Dihydro-4H-pyrazolo[3,4-d]pryimidin-4-one</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>02339</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ALLOPURINOL</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>63CZ7GJN5I</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>1H-Pyrazolo[3,4-d]pyrimidin-4-ol</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0001390</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Allopurinol</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>4-Hydroxypyrazolo[3,4-d]pyrimidine</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>allopurinol</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000045052</n0:source-code></n0:ComplexTerm>

nci:P97

<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. (NCI04)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>

nci:code

C224

owl:sameAs

n7:63CZ7GJN5I n8:N0000005830

n5:hasConcept

n6:M0000745